Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALSBOTHELL, Wash., Nov. 28, 2022 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced it will present…

Read the full article here

Source: finance.yahoo.com

Categories: Latest Headlines, Rare Disease

Tweets with this article

ALS Advocacy

Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND https://t.co/4EhmooiU7j via @YahooFinance

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University’s Lombardi Comprehensive Cancer Center NEW HAVEN,…

Benjamin Weinberg, MD, FACP April 26, 2024

On the Horizon: A Robot to Assist ALS Patients – SBU News

Interdisciplinary research team using AI, engineering, and knowledge of disease complications to create “CART” STONY BROOK, NY, April 25, 2024 – The debilitating disease of…

ALS Advocacy April 26, 2024

Letter by Letter, Steve Gleason Typed His Memoir With His Eyes (Gift Article)

The former N.F.L. player has been living with A.L.S. for more than a decade. Sharing “the most lacerating and vulnerable times” in “A Life Impossible”…

ALS Advocacy April 25, 2024

FDA’s biologics chief Peter Marks previews accelerated approval guidance

The FDA’s Center for Biologics Evaluation and Research is planning to release some crucial guidance soon for CRISPR and gene therapy developers on platform technologies,…

ALS Advocacy April 25, 2024

ALS Therapy Development Institute

We are the world’s foremost drug discovery lab focused solely on ALS -ALS TDI

ALS Advocacy April 24, 2024

Target ALS launches new data portal for research

A nonprofit medical research foundation has launched a data portal designed to help spur scientific breakthroughs for the disease amyotrophic lateral sclerosis (ALS).

ALS Advocacy April 24, 2024

Nanoparticles could help patients with MS, ALS, and Parkinson’s

Researchers say it’s possible for nanoparticles to go through the digestive system and deliver medicine directly to the brain tissue.

ALS Advocacy April 24, 2024

Pope Francis Receives in Audience Woman with Lateral Amyotrophic Sclerosis – ZENIT – English

“Mrs Zeza” expressed her firm conviction that her faith is stronger than any illness. Her testimony spread widely on the Vatican’s social networks, where her…

ALS Advocacy April 24, 2024

Affinia Therapeutics to Present Data on Novel Cardiotropic and BBB-Penetrant AAV Capsids and Preclinical Efficacy and Safety in Genetic Cardiomyopathies and Sporadic ALS at the American Society of Gene & Cell Therapy 2024 Annual Meeting

Affinia Therapeutics announced that new preclinical data on its novel AAV capsids for genetic cardiomyopathies and diseases of the central nervous system such as amyotrophic…

ALS Advocacy April 24, 2024

Rare diseases, ALS: approval from the Ministry of Justice to the right to non-verbal communication

The Ministry of Justice officially confirmed the conclusions of the National Council of Notaries on full support for the evolutionary interpretation of the notarial law…

ALS Advocacy April 24, 2024

Related Articles